STOCK TITAN

Editas Medicine Inc Stock Price, News & Analysis

EDIT Nasdaq

Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.

Editas Medicine Inc (NASDAQ: EDIT), a leader in CRISPR-based genome editing, provides this centralized hub for tracking all corporate developments and scientific advancements. Access real-time updates on clinical trial progress, regulatory milestones, and financial disclosures essential for monitoring this pioneering biotech firm.

This resource aggregates EDIT's press releases, partnership announcements, and peer-reviewed research findings. Investors will find critical updates on pipeline therapies for genetic disorders, while analysts gain insights into strategic initiatives shaping the genomic medicine landscape. Content spans quarterly earnings, intellectual property developments, and preclinical breakthroughs.

Key categories include therapy authorization updates, collaboration agreements with research institutions, and presentations at major medical conferences. All materials are sourced directly from Editas Medicine and verified financial filings to ensure reliability.

Bookmark this page for efficient tracking of EDIT's progress in developing CRISPR/Cas9 and Cas12a therapies. Check regularly for authoritative updates on one of biotech's most innovative gene-editing platforms.

Rhea-AI Summary

Editas Medicine (NASDAQ: EDIT) reported in vivo preclinical proof-of-concept data for EDIT-401 on October 9, 2025, showing robust LDL-cholesterol lowering in animal models.

Key readouts: ≥90% mean LDL-C reduction in non-human primates within 48 hours and in mice with high baseline LDL-C; a ≥6-fold mean increase in LDLR protein in NHP liver; LDL-C reductions were durable in a three-month mouse study. Data were presented at the ESGCT 32nd Annual Congress and will be posted on the company website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
-
Rhea-AI Summary

Editas Medicine (Nasdaq: EDIT) announced an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress in Seville, Spain, Oct 7–10, 2025.

Presentation: “A transformative LDL‑cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non‑human primates.”
Presenter: Linda Burkly, Ph.D., Executive VP & Chief Scientific Officer. Session: Gene Editing II, Ex Vivo Applications on Thursday, Oct 9 at 5:00 p.m. CEST / 11:00 a.m. ET. Final Abstract No. OR069. Abstracts are available to registrants.

Management will also appear at two investor events in October: H.C. Wainwright Genetic Medicines Virtual Conference (fireside chat, Oct 14) and Chardan 9th Annual Genetic Medicines Conference panel (Oct 21, New York). Live webcasts and archived replays will be available in the company Investors section for about 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
conferences
-
Rhea-AI Summary

Editas Medicine (Nasdaq: EDIT) has nominated EDIT-401 as its lead in vivo development candidate, marking a significant milestone in gene editing therapeutics. This experimental therapy aims to reduce LDL cholesterol levels through a one-time treatment, achieving approximately 90% mean LDL-C reduction in non-human primate studies.

The company expects to deliver human proof-of-concept data by the end of 2026 and maintains a strong financial position with operational runway extending into the second quarter of 2027. Editas will host a company-sponsored webinar today to discuss EDIT-401's development and potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
none
Rhea-AI Summary

Editas Medicine (Nasdaq: EDIT), a leading gene editing company, has scheduled a webinar for Tuesday, September 2, 2025, at 8:00 a.m. ET to announce their lead in vivo development candidate. The presentation will be accessible through a webcast link and the company's investor relations website.

The webinar will focus on revealing details about their latest advancement in gene editing technology aimed at developing transformative medicines for serious diseases. A replay will be available in the Investors section of the Editas Medicine website following the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
conferences
-
Rhea-AI Summary

Editas Medicine (NASDAQ: EDIT), a gene editing company, has announced its participation in three major healthcare investor conferences in September 2025. The company will attend the Wells Fargo Healthcare Conference on September 3 in Boston, the Cantor Global Healthcare Conference on September 4 in New York featuring a fireside chat at 11:30 a.m. ET, and the Baird Global Healthcare Conference on September 9 in New York.

Live webcasts of available presentations can be accessed through the Investors section of Editas Medicine's website, with replays available for approximately 30 days after each event.

[]
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
-
Rhea-AI Summary

Editas Medicine (Nasdaq: EDIT) reported Q2 2025 financial results and business updates. The company plans to select its first in vivo development candidate in September, targeting an IND filing by mid-2026 and human proof-of-concept by year-end 2026. Key highlights include the acceptance of first IND/CTA for CD19 HD Allo CAR T program with Bristol Myers Squibb and presentation of promising preclinical data at multiple scientific conferences.

Financial results show a net loss of $53.2 million ($0.63 per share), improved from $67.6 million loss in Q2 2024. The company maintains a strong cash position of $178.5 million, providing runway into Q2 2027. Research and development expenses decreased to $16.2 million from $54.2 million year-over-year, while restructuring charges were $26.1 million related to the discontinuation of the reni-cel program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.5%
Tags
Rhea-AI Summary
Editas Medicine (NASDAQ: EDIT) reported promising preclinical data for its in vivo gene editing treatment for sickle cell disease and beta thalassemia. Using proprietary targeted lipid nanoparticle (tLNP) delivery, the company achieved 58% mean editing in hematopoietic stem cells (HSCs) at five months after a single dose in non-human primates, significantly exceeding the 25% threshold needed for therapeutic benefit. The treatment targets HBG1/2 promoters to increase fetal hemoglobin production, mimicking natural mechanisms. Notably, the biodistribution data showed significant liver de-targeting compared to standard LNPs. The data will be presented at the European Hematology Association 2025 Congress in Milan, Italy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.39%
Tags
none
-
Rhea-AI Summary

Editas Medicine (NASDAQ: EDIT) announced the acceptance of new preclinical data for presentation at the European Hematology Association (EHA) 2025 Congress in Milan. The study, conducted in non-human primates, demonstrates promising results for their in vivo hematopoietic stem cell (HSC) gene editing program targeting sickle cell disease and beta thalassemia.

Key findings include high-efficiency HSC delivery, therapeutically relevant editing levels in the HBG1/2 promoter region exceeding 25% threshold with a single dose, and favorable biodistribution using Editas' targeted lipid nanoparticle (tLNP) technology. The data shows significant liver de-targeting compared to standard LNPs, supporting further development of their proprietary HSC-tLNP platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
conferences
-
Rhea-AI Summary
Editas Medicine (NASDAQ: EDIT) has reported promising new in vivo data for its gene editing therapy targeting sickle cell disease and beta thalassemia. The study demonstrated high efficiency in editing HBG1/2 promoters in hematopoietic stem cells (HSCs) using their proprietary targeted lipid nanoparticle (tLNP) delivery system. Key findings include:

In non-human primates, a single intravenous dose achieved up to 47% HBG1/2 editing levels in HSCs. In humanized mice, the treatment reached 48% editing in long-term HSCs. Both results exceeded the 25% threshold required for therapeutic benefit.

The company's tLNP formulation showed improved liver de-targeting compared to standard LNPs, and utilizes proprietary AsCas12a technology for high-efficiency editing while minimizing off-target effects. The approach mimics naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
none
Rhea-AI Summary
Editas Medicine (NASDAQ: EDIT) presented promising in vivo proof of concept data for an undisclosed liver target at the ASGCT Annual Meeting. The study demonstrated successful gene editing using lipid nanoparticles with CRISPR/Cas RNA cargo. Key results include:
  • ~70% maximal liver editing and >80% disease biomarker reduction in mouse models
  • >50% target gene editing and >15-fold protein upregulation in cynomolgus monkey hepatocytes
The editing strategy mimics a naturally occurring protective variant to upregulate the target gene. The company plans to reveal the specific disease target and development candidate later in 2025. Additional data will be presented at the TIDES USA 2025 Conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
none

FAQ

What is the current stock price of Editas Medicine (EDIT)?

The current stock price of Editas Medicine (EDIT) is $3.96 as of October 16, 2025.

What is the market cap of Editas Medicine (EDIT)?

The market cap of Editas Medicine (EDIT) is approximately 365.1M.
Editas Medicine Inc

Nasdaq:EDIT

EDIT Rankings

EDIT Stock Data

365.08M
89.65M
0.3%
49.2%
8.69%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE